Pages that link to "Item:Q7"
Jump to navigation
Jump to search
The following pages link to Segment (Q7):
View (previous 50 | next 50) (20 | 50 | 100 | 250 | 500)- Section 3.4.1: Severe type (from DOI: 10.1080/22221751.2020.1735265) (Q8406) (← links)
- Section 3.4.2: Critically ill type (from DOI: 10.1080/22221751.2020.1735265) (Q8407) (← links)
- Section 3.5: Treatment (from DOI: 10.1080/22221751.2020.1735265) (Q8408) (← links)
- Section 3.5.1: General treatment (from DOI: 10.1080/22221751.2020.1735265) (Q8409) (← links)
- Section 3.5.2: Oxygen therapy (from DOI: 10.1080/22221751.2020.1735265) (Q8410) (← links)
- Section 3.5.2.1: Choice of oxygen therapy (from DOI: 10.1080/22221751.2020.1735265) (Q8411) (← links)
- Section 3.5.2.2: The way of respiratory support (from DOI: 10.1080/22221751.2020.1735265) (Q8412) (← links)
- Section 3.5.3: Antiviral treatment (from DOI: 10.1080/22221751.2020.1735265) (Q8413) (← links)
- Section 3.5.4: Glucocorticoid therapy (from DOI: 10.1080/22221751.2020.1735265) (Q8414) (← links)
- Section 3.5.5: Intravenous immunoglobulin (from DOI: 10.1080/22221751.2020.1735265) (Q8415) (← links)
- Section 3.5.6: Empirical antimicrobial therapy (from DOI: 10.1080/22221751.2020.1735265) (Q8416) (← links)
- Section 4: Protection and transfer (from DOI: 10.1080/22221751.2020.1735265) (Q8417) (← links)
- Section 5: Criteria of isolation release and discharge (from DOI: 10.1080/22221751.2020.1735265) (Q8418) (← links)
- Disclosure statement (from DOI: 10.1080/22221751.2020.1735265) (Q8419) (← links)
- Section 1: Introduction (from DOI: 10.1038/s41392-020-0110-5) (Q8462) (← links)
- Section 2: The concept of CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8463) (← links)
- Section 2.1: Biological characteristics of CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8464) (← links)
- Section 2.2: Isolation and identification of CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8465) (← links)
- Section 3: Factors regulating CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8466) (← links)
- Section 3.1: Major transcription factors in CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8467) (← links)
- Section 3.2: Major signaling pathways in CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8468) (← links)
- Section 3.2.1: Wnt signaling pathway in CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8469) (← links)
- Section 3.2.2: Notch signaling pathway in CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8470) (← links)
- Section 3.2.3: Hh signaling pathway in CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8471) (← links)
- Section 3.2.4: NF-kappaB signaling pathway in CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8472) (← links)
- Section 3.2.5: JAK-STAT signaling pathway (from DOI: 10.1038/s41392-020-0110-5) (Q8473) (← links)
- Section 3.2.6: TGF/SMAD signaling pathway in CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8474) (← links)
- Section 3.2.7PI3K/AKT/mTOR signaling pathway in CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8475) (← links)
- Section 3.2.8: PPAR signaling pathways in CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8476) (← links)
- Section 3.2.9: Interactions between signaling pathways in CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8477) (← links)
- Section 3.3: The microenvironment of CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8478) (← links)
- Section 3.3.1: Vascular niche microenvironments and CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8479) (← links)
- Section 3.3.2: The hypoxia microenvironment and CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8480) (← links)
- Section 3.3.3: Tumor-associated macrophages and CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8481) (← links)
- Section 3.3.4: Cancer-associated fibroblasts and CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8482) (← links)
- Section 3.3.5: Cancer-associated MSCs and CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8483) (← links)
- Section 3.3.6: Extracellular matrix and CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8484) (← links)
- Section 3.3.7: Exosomes in the TME and CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8485) (← links)
- Section 4: Therapeutic targeting of CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8486) (← links)
- Section 4.1: Agents targeting CSC-associated surface biomarkers in clinical trials (from DOI: 10.1038/s41392-020-0110-5) (Q8487) (← links)
- Section 4.2: Agents targeting CSC-associated signaling pathways in clinical trials (from DOI: 10.1038/s41392-020-0110-5) (Q8488) (← links)
- Section 4.3: Targeting the CSC microenvironment (from DOI: 10.1038/s41392-020-0110-5) (Q8489) (← links)
- Section 4.4: CSC-directed immunotherapy (from DOI: 10.1038/s41392-020-0110-5) (Q8490) (← links)
- Section 5: Conclusions and perspectives (from DOI: 10.1038/s41392-020-0110-5) (Q8491) (← links)
- Competing interests (from DOI: 10.1038/s41392-020-0110-5) (Q8492) (← links)
- Section 1. Introduction (from DOI: 10.3390/v12020211) (Q10062) (← links)
- Section 2. Traditional Methods of Diagnosing Infections (from DOI: 10.3390/v12020211) (Q10063) (← links)
- Section 3. Studying Viral Pathogens with High Throughput Sequencing (HTS) (from DOI: 10.3390/v12020211) (Q10064) (← links)
- Section 3.1. Metagenomic Approach (from DOI: 10.3390/v12020211) (Q10065) (← links)
- Section 3.2. Problems of Metagenomic Approach (from DOI: 10.3390/v12020211) (Q10066) (← links)